Adrenomed AG

Adrenomed AG: Adrenomed is a German biopharmaceutical company specialized in preserving vascular integrity in life-threatening conditions by precision medicine. Adrecizumab, clinical stage, first-in-class monoclonal antibody, targets the vasoprotective peptide Adrenomedullin, to treat conditions associated with increased vascular leakage, endothelial barrier dysfunction and shock. Successfully concluded clinical AdrenOSS-2 trial, a biomarker-guided, double-blind, placebo-controlled, randomized, multicenter proof-of-concept Phase 2 trial, in 301 septic shock patients. Single infusion of Adrecizumab resulted in a significant and fast improvement of mean fluid balance, a surrogate endpoint for vascular leakage. Within 24 hours, Adrecizumab led to a significant and sustained improvement of systemic organ function (SOFA score). Subsequently, the relative mortality was significantly reduced by more than 50% after day 28 which persisted over 90 days. Excellent safety and tolerability demonstrated in P2 in addition to two Phase I trials. TAM ~ 350K septic shock patients in 7MM. Business is Effectively Protected by Strong IP Position.
Sector/Industry:
Healthcare
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Cardiovascular, Infectious Disease
Industry
Biotechnology, Pharmaceuticals
Investment Participation
Series C
Listing
Private
Therapeutic Modalities
Antibodies
Website:
Profiles:
Address:
Neuendorfstraße 15A
Henningsdorf
Berlin, Berlin 16761
Germany

Company Participants at Solebury Trout Virtual Global Healthcare Conference Series

  • Jens Schneider-Mergener , PhD, CEO

Upcoming Company Event Participation